LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Отворен

СекторЗдравеопазване

2.87 1.77

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.8

Максимум

2.96

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+624.64% upside

Дивиденти
By Dow Jones
Следващи печалби	2.06.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-139M 250M
Предишно отваряне	1.1
Предишно затваряне	2.87

Настроения в новините

By Acuity

67%

33%

295 / 344 Класиране в Healthcare

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.05.2026 г., 22:47 ч. UTC

Печалби

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28.05.2026 г., 20:45 ч. UTC

Печалби

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28.05.2026 г., 23:31 ч. UTC

Пазарно говорене

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28.05.2026 г., 23:02 ч. UTC

Пазарно говорене

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28.05.2026 г., 22:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.05.2026 г., 22:41 ч. UTC

Пазарно говорене

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28.05.2026 г., 22:37 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

M&A-Related Insurance Payments In North America Rise -- Market Talk

28.05.2026 г., 22:04 ч. UTC

Придобивния, сливания и поглъщания

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28.05.2026 г., 22:04 ч. UTC

Придобивния, сливания и поглъщания

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28.05.2026 г., 21:12 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28.05.2026 г., 21:00 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28.05.2026 г., 20:57 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings -- Barrons.com

28.05.2026 г., 20:55 ч. UTC

Печалби

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

28.05.2026 г., 20:48 ч. UTC

Горещи акции

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28.05.2026 г., 20:34 ч. UTC

Печалби

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28.05.2026 г., 20:31 ч. UTC

Печалби

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28.05.2026 г., 20:28 ч. UTC

Печалби

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28.05.2026 г., 20:26 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings -- Barrons.com

28.05.2026 г., 20:20 ч. UTC

Печалби

Costco 3Q Membership Fees $1.37B

28.05.2026 г., 20:20 ч. UTC

Печалби

Costco 3Q Net Sales $69.15B

28.05.2026 г., 20:19 ч. UTC

Печалби

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28.05.2026 г., 20:19 ч. UTC

Печалби

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28.05.2026 г., 20:17 ч. UTC

Печалби

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28.05.2026 г., 20:17 ч. UTC

Печалби

Costco 3Q Same-Store Sales Up 9.8% >COST

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

624.64% нагоре

12-месечна прогноза

Среден 20 USD 624.64%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Настроение

By Acuity

295 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.